Press Release

Frequency Therapeutics Expands Leadership Team with Newly Appointed Chief People Officer and Head of Intellectual Property

February 7, 2020 at 8:00 AM EST

WOBURN, Mass.--(BUSINESS WIRE)--Feb. 7, 2020-- Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced new appointments to its leadership team. Wendy Arnold has joined the company as Chief People Officer, and Lisa Geller, Ph.D., J.D., is the company’s new Head of Intellectual Property.

These additions help to strengthen the organization as it advances development of its lead product candidate, FX-322, a regenerative therapeutic for the treatment of sensorineural hearing loss now in Phase 2a study, as well as its discovery programs in multiple sclerosis and other therapeutic areas where the activation of progenitor cells may be used to create novel regenerative therapies.

“During this time of strategic growth, it is critical to have the structure in place to build an organization that enables us to drive our clinical efforts forward, expand upon the potential of our science and continue to build a culture that attracts world-class talent,” said David Lucchino, Frequency’s President and Chief Executive Officer. “These two leaders bring tremendous experience to Frequency and will play critical roles as we work to develop a potential medicine to repair damage to cells that cause the most common form of hearing loss and to build a pipeline of regenerative therapies based on our progenitor cell activation platform.”

Ms. Arnold joins Frequency from Kaleido BioSciences, where she was Senior Vice President of Human Resources. At Kaleido, she helped lead the human resources organization during a period of rapid growth, including implementing talent and engagement initiatives, and a framework for leadership and performance management. Prior to that she held senior roles in the human resources organization at Moderna Therapeutics, and she brings extensive industry professional experience from her roles at Celgene, Predictive Biosciences and Inotek Pharmaceuticals and work at other small to mid-size public and private companies. Ms. Arnold holds a Bachelor of Science from Colorado State University.

Dr. Geller is an experienced patent attorney with both law firm and in-house experience in the biotechnology and pharmaceutical sectors. Prior to joining Frequency, she was Head of Intellectual Property at Casebia Therapeutics, where she was responsible for all aspects of intellectual property including patent, trademark and trade secrets. She also brings extensive experience from companies such as Seres Therapeutics, Eleven Biotherapeutics and Biogen, and the law firms of Wilmer Cutler Pickering Hale & Dorr and Fish & Richardson P.C. Dr. Geller earned her Bachelor of Arts in Biology and Psychology from Pitzer College, her Ph.D. in biology from University of California, Los Angeles, and her Juris Doctor in Law from the Boston University School of Law. Dr. Geller has published articles on topics related to the interface between social issues and science, and she currently serves on the board of Science and Engineering Ethics.

About Frequency Therapeutics

Frequency Therapeutics is a leader in the development of medicines designed to activate progenitor cells within the body to treat degenerative diseases. The Company’s progenitor cell activation (PCA) approach stimulates progenitor cells to create functional tissue with the aim of developing disease modifying therapies. The Company’s lead product candidate, FX-322, is designed to regenerate auditory hair cells to restore hearing function. In a FX-322 Phase 1/2 study, statistically significant and clinically meaningful improvements in key measures of hearing function in patients with sensorineural hearing loss were observed. The Company also is evaluating additional diseases where its PCA approach could create functional tissue, including a discovery program in multiple sclerosis.

Headquartered in Woburn, Mass., Frequency has a license and collaboration agreement with Astellas Pharma Inc. for FX-322, for which it retains U.S. rights, as well as additional collaboration and licensing agreements with academic and nonprofit research organizations including The Scripps Research Institute, Massachusetts Eye and Ear, Partners Healthcare and the Massachusetts Institute of Technology. For more information, visit www.frequencytx.com and follow Frequency on Twitter @Frequencytx.

Source: Frequency Therapeutics, Inc.

Frequency Media Contact:
Suzanne Day
Frequency Therapeutics
Tel: 781-496-2211
Email: sday@frequencytx.com